OCULAR THERAPEUTICS AND DRUG DELIVERY
A MULTI-DISCIPLINARY APPROACH

Edited by
Indra K. Reddy, Ph.D.
Associate Professor of Pharmaceutics
College of Pharmacy and Health Sciences
Northeast Louisiana University
Table of Contents

Foreword xv

Preface xvii

Acknowledgements xxi

Contributing Authors xxiii

PART I: OVERVIEW, BASIC PRINCIPLES AND METHODOLOGY

1. OCULAR THERAPEUTICS AND DRUG DELIVERY: AN OVERVIEW .............................................. 3
INDRA K. REDDY and MADURAI G. GANESAN

Introduction 3
Structures of the Eye 4
Common Diseases of the Eye 5
Routes of Administration for Ocular Therapeutics 6
Ocular Drug Disposition 9
Ocular Bioavailability 12
Pharmacokinetics in Ocular Drug Delivery 13
Drug Metabolism in Ocular Tissues 14
Conventional Ophthalmic Dosage Forms 15
Ophthalmic Drug Delivery Systems 15
Chemical/Biochemical Approaches to Drug Delivery 16
Ocular Delivery of Proteins and Peptides 19
Animal Models 19
Ocular Toxicity 21
| Conclusion | 22 |
| References | 23 |

2. **SURFACE CHEMICAL ASPECTS OF OCULAR DRUG DELIVERY SYSTEMS** .......................... 31  
C. P. SINGH and DINESH O. SHAH

| Introduction | 31 |
| Wetting | 33 |
| Hydrogen Ion Concentration (pH) | 34 |
| Viscosity | 36 |
| Oil-Water Partitioning | 39 |
| Micellar Solubilization | 42 |
| Osmolality | 43 |
| Conclusion | 43 |
| References | 44 |

3. **BIOLOGICAL BARRIERS TO OCULAR DELIVERY** ............. 51  
JOHN C. LANG and MONICA M. STIEMKE

| Introduction | 51 |
| Processes and Phenomenological Barriers | 52 |
| Structure and Function | 75 |
| Experimental Models: Utility and Limitations | 88 |
| Conclusions | 94 |
| Appendix A | 95 |
| Appendix B | 107 |
| Appendix C | 109 |
| Appendix D | 111 |
| Appendix E | 112 |
| Appendix F | 115 |
| Appendix G | 120 |
| Appendix H | 122 |
| References | 126 |

4. **PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATIONS OF OPHTHALMIC DRUGS** ............ 133  
DIANE D.-S. TANG-LIU, ANDREW ACHEAMPONG, DU-SHIENG CHIEN and JOEL. I. USANSKY

| Introduction | 133 |
| Brimonidine | 135 |
| Prostaglandin F<sub>2α</sub> Prodrugs | 137 |
| Ofloxacin | 142 |
| Conclusion | 144 |
Table of Contents

Acknowledgements 144
References 144

5. DRUG METABOLIZING ENZYME SYSTEMS IN THE EYE .................................................. 149
GONDI N. KUMAR

Introduction 149
Phase I Enzymes 150
Phase II Enzymes 157
Significance of Ocular Metabolism 161
References 162

PART II: PATHOPHARMACOLOGY AND CLINICAL APPLICATIONS

6. ARTIFICIAL TEAR FORMULATIONS, IRRIGATING SOLUTIONS AND CONTACT LENS PRODUCTS .......... 171
INDRA K. REDDY, WAHEED AZIZ and ROBERT B. SAUSE

Introduction 171
Artificial Tear Formulations 171
Irrigating Solutions 185
Contact Lens Products 193
Conclusion 204
References 205

7. CLINICAL PHARMACOLOGY OF THE ANTERIOR SEGMENT OF THE EYE ................................. 213
MICHAEL A. BARTLETTA and INDRA K. REDDY

Introduction 213
Clinical Ophthalmic Examination for the Etiology of Disease 213
Common Ocular Disorders 214
Local Anesthetics 218
Anti-Inflammatory Agents 222
Anti-Infective Agents 228
Conclusion 239
References 240

8. RECENT DEVELOPMENTS IN ANTI-GLAUCOMA DRUG RESEARCH ........................................ 245
MARKKU LEINO and ARTO URTTI

Introduction 245
Cholinergic Drugs 246
Topical Carbonic Anhydrase Inhibitors 247
Adrenergic Drugs 249
Cannabinoids 252
Prostaglandins 253
Ethachrynic Acid 254
Delivery Systems and Systemic Absorption of Topical Glaucoma Drugs 255
References 257

9. VITREORETINAL DISEASES: PATHOLOGICAL ASPECTS AND THERAPEUTIC STRATEGIES 265
GHOLAM A. PEYMAN

Introduction 265
Endophthalmitis 266
Proliferative Vitreoretinopathy 269
Viral Retinitis 272
References 273

PART III: CHEMICAL/BIOCHEMICAL APPROACHES TO OCULAR DRUG DELIVERY

10. PRODRUGS: A CHEMICAL APPROACH TO OCULAR DRUG DELIVERY 285
VIJAY K. TAMMARA and MICHAEL A. CRIDER

Introduction 285
Prodrug Forms of Various Functional Groups 287
Enzymes Responsible for Bioconversion 289
Kinetic Profiles of Prodrugs 294
Selected Case Studies of Prodrugs 296
Future Perspectives/Conclusions 323
References 324

11. THE USE OF RETROMETABOLIC DRUG DESIGN CONCEPTS IN OPHTHALMIC DRUG DISCOVERY 335
NICHOLAS BODOR

Introduction 335
Retrometabolic Design of Novel Anti-Glaucoma Drugs 339
The Inactive Metabolite Approach in the Design of Soft Corticosteroids 351
Soft Anticholinergic Agents as Short-Acting Mydriatics 356
Conclusion 358
Acknowledgements 359
References 359
12. DEVELOPMENT OF SOFT DRUGS FOR OPHTHALMIC USE .................................................. 363
JOHN F. HOWES

Introduction 363
Loteprednol Etabonate 363
Adaprolol Maleate 372
References 373

PART IV: FORMULATION AND DRUG DELIVERY CONSIDERATIONS

13. TOPICAL OPHTHALMIC FORMULATIONS: BASIC CONSIDERATIONS .............................. 377
NUTAN K. GANGRADE, NEHRU B. GADDIPATI, MADURAI G. GANESAN and INDRA K. REDDY

Introduction 377
Adjuvants 379
Sterility 391
Suspensions and Particulates 395
Semisolid Ophthalmic Formulations 396
Conclusion 398
References 399

14. POLYMERS IN OPHTHALMIC DRUG DELIVERY SYSTEMS .............................................. 405
MANSOOR A. KHAN and MANZER J. DURRANI

Introduction 405
Classification 405
Physicochemical Properties of the Polymers 408
Applications of Polymers in the Eye 417
Conclusions 430
Acknowledgements 431
References 431

15. MICROPARTICULATES AS AN OCULAR DELIVERY SYSTEM ............................................ 441
ABHAY JOSHI

Introduction 441
Limitations on Ocular Drug Delivery 442
Microparticulates as an Injectable Drug Delivery System 445
Microparticulates as a Topical Ocular Delivery System 448
Multiparticulate Manufacture and Formulation Challenges 455
<table>
<thead>
<tr>
<th>Table of Contents</th>
</tr>
</thead>
</table>

**Conclusion** 456  
References 457

### 16. PROTEIN AND PEPTIDE DRUG DELIVERY TO THE EYE 461
AJAY K. BANGA

- Introduction 461
- Overview of Relevant Structural Details for Peptide/Protein Drugs 463
- Formulation Considerations for Peptide/Protein Solutions 463
- Ocular Administration of Peptides/Proteins for Topical Effects 468
- Systemic Delivery of Peptides/Proteins through the Eye 472
- Specialized Delivery Systems 477
- Conclusions 480
- References 480

### 17. EVALUATION OF PRIMARY OCULAR IRRITATION: ALTERNATIVES TO THE DRAIZE TEST 489
CHRISTINE M. HUTAK and RICHARD B. JACARUSO

- Introduction 489
- Draize Test 489
- Objections to the Draize Test 490
- Alternative *in vivo* Assays 493
- Alternative *in vitro* Assays 493
- Anatomy of the Cornea and Its Relation to Ocular Irritation and Corneal Opacification 499
- The Inflammatory Response 500
- Permeotoxicity 502
- Efficacy of *in vitro* Methods 503
- Validation of *in vitro* Tests 505
- Validation of a Proposed Battery of *in vitro* Tests 509
- Conclusion 512
- References 513

**PART V: INDUSTRIAL AND REGULATORY CONSIDERATIONS**

### 18. PACKAGING ASPECTS OF OPHTHALMIC PRODUCTS 529
NEHRU B. GADDIPATI, NUTAN K. GANGRADE, MADURAI G. GANESAN and INDRA K. REDDY

- Introduction 529
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ophthalmic Drops (Solutions/Suspensions)</td>
<td>530</td>
</tr>
<tr>
<td>Ophthalmic Ointments</td>
<td>536</td>
</tr>
<tr>
<td>Novel Ophthalmic Packages</td>
<td>536</td>
</tr>
<tr>
<td>Ophthalmic Packaging Standards</td>
<td>540</td>
</tr>
<tr>
<td>Conclusion</td>
<td>540</td>
</tr>
<tr>
<td>References</td>
<td>540</td>
</tr>
<tr>
<td>19. A BRIEF HISTORY OF DRUG REGULATION AND REGULATORY ISSUES GOVERNING</td>
<td>543</td>
</tr>
<tr>
<td>OPTHALMIC PRODUCTS: A BIOPHARMACEUTIC PERSPECTIVE</td>
<td></td>
</tr>
<tr>
<td>VIJAY K. TAMMARA, RAMAN K. BAWEJA, ANGELICA DORANTES and JOHN P. HUNT</td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>543</td>
</tr>
<tr>
<td>History of Drug Regulations in the United States</td>
<td>544</td>
</tr>
<tr>
<td>Regulatory Issues/Requirements</td>
<td>549</td>
</tr>
<tr>
<td>Bioregulations</td>
<td>557</td>
</tr>
<tr>
<td>Labeling Requirements</td>
<td>564</td>
</tr>
<tr>
<td>Summary</td>
<td>568</td>
</tr>
<tr>
<td>Glossary</td>
<td>568</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>573</td>
</tr>
<tr>
<td>References</td>
<td>573</td>
</tr>
</tbody>
</table>

Index 575

About the Editor 587